MaiCell Therapeutics

MaiCell Therapeutics is a UK-based biotechnology company specializing in the development of off-the-shelf cell therapies using induced pluripotent stem cells (iPSCs). A spin-out from the University of Sheffield, the company utilizes proprietary technology to ensure the genetic stability and safety of stem cell lines intended for clinical use. Their platform focuses on creating universal donor cells that can be differentiated into various therapeutic cell types, such as Natural Killer (NK) cells, to treat oncology indications without the need for patient-specific matching. By addressing the scalability and cost challenges of first-generation cell therapies, MaiCell aims to make advanced immunotherapy more accessible. The company is backed by prominent investors including Northern Gritstone and Parkwalk Advisors.